SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Business
Good Science Doesn’t Guarantee Success: Why Some Biotech Startups Fail
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
February 17, 2022
 · 
6 min read
 · 
Gail Dutton
Biotech Bay
What BioSpace Heard at the BIO CEO & Investor Conference
BioSpace learned that growing functional organs may indeed be possible, and about the role of protein-to-protein interactions in cancer immunotherapy.
February 17, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Infusion Clinics are Key to Preparing Psychedelics for the Healthcare System
Psychedelics therapies – serotonin 2 A receptor agonists – are trying to enter mainstream medicine for depression and as anti-inflammatory or neuroprotective treatments.
February 16, 2022
 · 
6 min read
 · 
Gail Dutton
Image courtesy of Getty Images
Business
TenSixteen Bio Plumbs Somatic Mosaicism for Source of Multiple Diseases
TenSixteen Bio recently came out of stealth mode with $40 million in funding to target somatic mosaicism – particularly clonal hematopoiesis of indeterminate potential (CHIP).
February 16, 2022
 · 
3 min read
 · 
Gail Dutton
Business
Genomenon Scores $1.7M SBIR Grant to Curate Genetic Drivers of Disease
The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.
February 15, 2022
 · 
4 min read
 · 
Gail Dutton
Exo CEO Michael Bruce/courtesy of Exo Therapeutics
Business
ID’ing Exosites to Enable Specificity and Drug Intractable Targets
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
February 13, 2022
 · 
6 min read
 · 
Gail Dutton
Policy
AACR Calls for More Funding for Basic Research and Telehealth Equity
The speakers extolled the benefits of telehealth while noting the challenges posed by a lack of high-speed Internet in some parts of the country.
February 10, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Endevica Bio Makes Cancer Scourge Cachexia Waste Away
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
February 8, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Multiple Studies Illustrate the Widespread Damage Wrought by COVID-19
COVID-19 causes certain conditions or is being implicated in their earlier onset. Type 1 diabetes and Parkinson’s disease are prime examples. According to researchers, it also may cause fetal inflammation.
February 5, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Precision Nutrition – the Untapped Reservoir in Cancer Therapeutics
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
February 4, 2022
 · 
5 min read
 · 
Gail Dutton
OcuTerra CEO Kerrie Brady_Courtesy OcuTerra Therap
Drug Development
CEO Kerrie Brady Organizes OcuTerra for Success Against Diabetic Retinopathy
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
February 1, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Lithium-Sparing Alzheimer’s Therapy has Strong Benefit-to-Risk Profile
Alzamend Neuro is looking to commence a Phase II multiple ascending dose study of lead compound, AL001, in Alzheimer’s disease during the second quarter of this year.
January 27, 2022
 · 
5 min read
 · 
Gail Dutton
BioMidwest
From Zero to Hero: Biopharma’s Pivotal Inflection Point
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
January 26, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
BlueWillow’s Non-Viral Intranasal Vaccine Enhances Immunity and Broadens Options
In addition to the induction of both mucosal and systemic immunity, advantages of an intranasal approach include the lack of needles, low cost and thermostability under normal refrigeration temperature.
January 25, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
AstraZeneca’s Hematology Cornerstone is “Completely Replacing” Previous Standards
BioSpace sat down with Niko Andre, M.D., Ph.D., global franchise head for hematology and immuno-oncology at AstraZeneca.
January 24, 2022
 · 
4 min read
 · 
Gail Dutton
Load More